These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202 [TBL] [Abstract][Full Text] [Related]
3. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Thakore PI; D'Ippolito AM; Song L; Safi A; Shivakumar NK; Kabadi AM; Reddy TE; Crawford GE; Gersbach CA Nat Methods; 2015 Dec; 12(12):1143-9. PubMed ID: 26501517 [TBL] [Abstract][Full Text] [Related]
4. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Hilton IB; D'Ippolito AM; Vockley CM; Thakore PI; Crawford GE; Reddy TE; Gersbach CA Nat Biotechnol; 2015 May; 33(5):510-7. PubMed ID: 25849900 [TBL] [Abstract][Full Text] [Related]
5. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing. Goubert D; Koncz M; Kiss A; Rots MG Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148 [TBL] [Abstract][Full Text] [Related]
6. Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing. Moses C; Hodgetts SI; Nugent F; Ben-Ary G; Park KK; Blancafort P; Harvey AR Sci Rep; 2020 Jul; 10(1):11393. PubMed ID: 32647121 [TBL] [Abstract][Full Text] [Related]
7. Genome and epigenome engineering CRISPR toolkit for Williams RM; Senanayake U; Artibani M; Taylor G; Wells D; Ahmed AA; Sauka-Spengler T Development; 2018 Feb; 145(4):. PubMed ID: 29386245 [TBL] [Abstract][Full Text] [Related]
8. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis. Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825 [TBL] [Abstract][Full Text] [Related]
9. In vivo epigenome editing and transcriptional modulation using CRISPR technology. Lau CH; Suh Y Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145 [TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity. Tadić V; Josipović G; Zoldoš V; Vojta A Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448 [TBL] [Abstract][Full Text] [Related]
12. Antagonistic and synergistic epigenetic modulation using orthologous CRISPR/dCas9-based modular system. Josipović G; Tadić V; Klasić M; Zanki V; Bečeheli I; Chung F; Ghantous A; Keser T; Madunić J; Bošković M; Lauc G; Herceg Z; Vojta A; Zoldoš V Nucleic Acids Res; 2019 Oct; 47(18):9637-9657. PubMed ID: 31410472 [TBL] [Abstract][Full Text] [Related]
13. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775 [TBL] [Abstract][Full Text] [Related]
14. Generation and validation of versatile inducible CRISPRi embryonic stem cell and mouse model. Li R; Xia X; Wang X; Sun X; Dai Z; Huo D; Zheng H; Xiong H; He A; Wu X PLoS Biol; 2020 Nov; 18(11):e3000749. PubMed ID: 33253175 [TBL] [Abstract][Full Text] [Related]